This site is intended for Healthcare Professionals only.

GSK, Sanofi and Haleon shares slump on Zantac litigation concerns; J&J ends talcum powder sale


Share post:

Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims.

GSK shares were down 6.8 per cent, Sanofi’s were down 6.9 per cent and Haleon’s down per cent.

GSK and Sanofi at various points sold the drug — originally branded as Zantac — which US regulators ordered off the market in 2020. Haleon, spun out as an independent listed company last month, comprises consumer health assets once partly owned by GSK.

The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus.

The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a note.

The litigation has just started to be talked about more by investors and written about in the media, Barclays analyst Emily Field said in an email. “I think the panic… really comes down to market psychology as opposed to having learned anything new.”

Zantac became the world’s best selling medicine in 1988 and one of the first-ever drugs to top $1 billion in annual sales.

However, concerns around the compound — known chemically as ranitidine — containing potential cancer-causing impurities started to emerge in 2018, well after generic versions of the medicine had been launched by a variety of manufacturers.

More than 2,000 legal cases related to Zantac have now been filed in the United States, analysts say, with the first trial beginning later this month.

“It is very possible we may see a liability of some $bn magnitude,” the Deutsche Bank analysts wrote.

Uncertainty over the issue has sparked fears of a worse-case scenario where costs run into the billions of dollars, as happened in cases involving Merck & Co’s painkiller Vioxx and Bayer’s glyphosate-based weedkiller.

Not primarily liable

A decline of as much as 12 per cent in Haleon shares on Thursday meant some $5 billion had been knocked off its value this week. It recovered some of those losses after a spokesperson said the company was not primarily liable for any claim.

“We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare,” the person said.

Zantac, originally marketed by a forerunner of GSK, has been sold by several companies since the late 1990s, including Pfizer, Boehringer Ingelheim and Sanofi.

That “may make third parties liable ahead of any Haleon exposure,” the Haleon spokesperson added.

A Pfizer spokesperson said in an email: “Pfizer, which has not sold a Zantac product in more than 15 years and did so only for a limited period of time, will continue to defend itself vigorously.”

Pfizer shares were down about 3 per cent.

A Boehringer spokesperson said via email the company would defend itself against any allegations, while Sanofi issued a statement saying it remained confident in its legal defenses and that there had not been any material developments regarding the US Zantac litigation.

GSK and Pfizer have each served Haleon with notice of potential claims of indemnification — but indemnification has not yet been determined between the parties, the Haleon spokesperson said.

After US and European regulators said they were reviewing Zantac’s safety in 2018, some manufacturers voluntarily took their version off the shelves.

By 2020, the US Food and Drug Administration requested makers of all versions of the treatment to withdraw their products from the market.

Johnson and Johnson to end sales of talcum powder

Meanwhile, Johnson and Johnson (J&J) has said it will stop sales of its talc-based Johnson’s Baby Powder globally next year following thousands of lawsuits from people alleging that it causes cancer.

The lawsuits have largely come from women who allege that the talcum powder is contaminated with asbestos and has caused them to develop ovarian cancer. Despite the decision to pull the product, the company strongly deny the allegations, saying independent research has shown the product to be completely safe.

The company, which owns brands like Listerine, Aveeno and Neutrogena, says that the talc-based powder will be replaced by a new corn starch-based product, adding that this was already sold in some of its markets.

In 2020, J&J halted sales of talc-based powder in the US and Canada because demand had fallen amid what it called “misinformation” prompted by the spate of lawsuits.

However, the product was still sold elsewhere across the world, including in the UK.

The company has sold its baby powder since 1894.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Superdrug to open 25 new high street stores this year

The opening of new Superdrug stores is anticipated to generate over 500 jobs nationwide Superdrug is bolstering its physical...

New Hospital Scheme delays drain millions monthly from ‘scarce’ NHS funds, trust leaders warn

Trust leaders are calling on the next government to commit to constructing 40 new hospitals in England by...

NHS virtual wards set to slash waiting times, prevent 178k admissions in next 2 years

Under the new NHS virtual wards scheme, hospitals to be incentivised for prompt care, with 12-hour A&E target In...

Pharmacist Support: Trainee pharmacists get set to ACTNow for mental health awareness ahead of GPhC assessment

Pharmacist Support's annual mental health awareness campaign offers vital support ahead of GPhC assessment and registration transition Trainee pharmacists...